target directory

anemia in chronic kidney disease ckd clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT03400033

Source recordAI-normalized

A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs

The ASCEND-TD trial evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against the standard of care, epoetin alfa, in hemodialysis patients with anemia. The study aimed to demonstrate daprodustat's efficacy and safety in maintaining hemoglobin levels.

AI analysis

Indication: Anaemia

Modality: small molecule

Target: Anemia in Chronic Kidney Disease (CKD)

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Jul 12, 2021

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia in Chronic Kidney Disease (CKD)

View original source fields

Condition raw: Anaemia

Condition normalized: Anaemia

Modality raw: Anaemia

Modality normalized: small molecule

Target raw: Anemia in Chronic Kidney Disease (CKD)

Target normalized: Anemia in Chronic Kidney Disease (CKD)

Open report

NCT03029247

Source recordAI-normalized

A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

The ASCEND-BP study evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against epoetin alfa in managing blood pressure in hemodialysis patients with anemia due to CKD. The study was sponsored by GlaxoSmithKline and involved 105 participants, with a focus on the drug's impact on systolic blood pressure.

AI analysis

Indication: Anaemia

Modality: small molecule

Target: Anemia in Chronic Kidney Disease (CKD)

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Jun 03, 2021

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia in Chronic Kidney Disease (CKD)

View original source fields

Condition raw: Anaemia

Condition normalized: Anaemia

Modality raw: Anaemia

Modality normalized: small molecule

Target raw: Anemia in Chronic Kidney Disease (CKD)

Target normalized: Anemia in Chronic Kidney Disease (CKD)

Open report

NCT03029208

Source recordAI-normalized

A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis

The ASCEND-ID trial evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against darbepoetin alfa in treating anemia in CKD patients initiating dialysis. Conducted by GlaxoSmithKline, the study aimed to establish daprodustat's efficacy and safety over a 52-week period.

AI analysis

Indication: Anaemia

Modality: small molecule

Target: Anemia in Chronic Kidney Disease (CKD)

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Oct 20, 2021

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia in Chronic Kidney Disease (CKD)

View original source fields

Condition raw: Anaemia

Condition normalized: Anaemia

Modality raw: Anaemia

Modality normalized: small molecule

Target raw: Anemia in Chronic Kidney Disease (CKD)

Target normalized: Anemia in Chronic Kidney Disease (CKD)

Open report